Search results
Results from the WOW.Com Content Network
Clinical-stage biotech Five Prime Therapeutics has a new bean counter. The San Francisco-based novel protein developer announced today that Marc Belsky has taken on the role of chief financial ...
Amgen (AMGN) inks a $1.9-billion deal to acquire clinical-stage biotech, Five Prime Therapeutics, to boost its oncology pipeline. Amgen (AMGN) to Add Stomach Cancer Drug With Five Prime Buyout ...
2021: In March, the company announced it would acquire Five Prime Therapeutics and its lead candidate, bemarituzumab, for $1.9 billion. [93] [94] [95] In the same month, Amgen acquired Rodeo Therapeutics for $720 million. [96] [97] The FDA approved Amgen's Lumakras in May for treatment of patients with KRAS-G12C-mutated non-small cell lung ...
It has the following product in pipeline: Cabiralizumab, FPA150, Bemarituzumab and Immuno-Oncology.Five Prime Therapeutics shares were trading up 20.53% at $5.30 on Monday. The stock has a 52-week ...
He is often featured on the Forbes Midas list and is currently on the board of directors of ten companies; CardioDX, Crescendo Bioscience, Inc., Genomic Health Incorporated, Five Prime Therapeutics, OptiMedica, HX Diagnostics, Pacific Biosciences, Inc., Tethys, Veracyte, Inc., and XDx, Inc. [4] Previously, he served on the board of directors of ...
Amgen has agreed to snap up clinical-stage biotech Five Prime Therapeutics for an equity value of $1.9 billion, to strengthen the company’s oncology candidates. Five Prime shares surged 78.7% to ...
Five Prime Therapeutics (FPRX) delivered earnings and revenue surprises of -21.31% and -41.49%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for ...
Change is in the air. A new President-elect and the possibility of an end to the pandemic. Some things, however, will always stay the same.Like small cap biotech stocks skyrocketing following the ...